



Article

In Vitro Fermentation of Selected Prebiotics and Their Effects on the Composition and Activity of the Adult Gut Microbiota

Sophie Fehlbaum ^{1,*}, Kevin Prudence ¹, Jasper Kieboom ², Margreet Heerikhuisen ²,
Tim van den Broek ², Frank H. J. Schuren ², Robert E. Steinert ¹  and Daniel Raederstorff ¹

¹ DSM Nutritional Products Ltd., R&D Human Nutrition and Health, 4002 Basel, Switzerland; kwprudence1200r@gmail.com (K.P.); robert.steinert@dsm.com (R.E.S.); daniel.raederstorff@dsm.com (D.R.)

² The Netherlands Organization for Applied Scientific Research (TNO), Microbiology and Systems Biology, 3704 HE Zeist, The Netherlands; jasper.kieboom@tno.nl (J.K.); margreet.heerikhuisen@tno.nl (M.H.); tim.vandenbroek@tno.nl (T.v.d.B.); frank.schuren@tno.nl (F.H.J.S.)

* Correspondence: sophie.fehlbaum@dsm.com

Received: 31 August 2018; Accepted: 3 October 2018; Published: 10 October 2018



Abstract: Recently, the concept of prebiotics has been revisited to expand beyond non-digestible oligosaccharides, and the requirements for selective stimulation were extended to include microbial groups other than, and additional to, bifidobacteria and lactobacilli. Here, the gut microbiota-modulating effects of well-known and novel prebiotics were studied. An *in vitro* fermentation screening platform (i-screen) was inoculated with adult fecal microbiota, exposed to different dietary fibers that had a range of concentrations (inulin, alpha-linked galacto-oligosaccharides (alpha-GOS), beta-linked GOS, xylo-oligosaccharides (XOS) from corn cobs and high-fiber sugar cane, and beta-glucan from oats), and compared to a positive fructo-oligosaccharide (FOS) control and a negative control (no fiber addition). All dietary fibers displayed prebiotic activity, with beta-glucan showing more distinct effects on the microbial composition and metabolism compared to the other fibers. Beta-glucan induced the growth of *Prevotella* and *Roseburia* with a concomitant increase in propionate production. Inulin and both forms of GOS and XOS had a strong bifidogenic effect on the microbial composition. A dose-response effect was observed for butyrate when exposed to beta-glucan and inulin. The findings of this study support the potential for alpha-GOS, XOS, and oat beta-glucan to serve as novel prebiotics, due to their association with the positive shifts in microbiome composition and short-chain fatty acid production that point to potential health benefits.

Keywords: XOS; beta-glucan; alpha-GOS; screening platform; i-screen; colonic fermentation

1. Introduction

The human intestine is colonized by a great number of microorganisms that contribute to host nutrition, metabolism, and immunity [1]. A structurally disrupted gut microbiota has been linked to the onset and development of various chronic diseases [2]. Dietary intervention to modulate the gut microbiota has become a potentially effective strategy to improve host health [3].

The concept of prebiotics was first introduced by Gibson and Roberfroid in 1995 [4], and over the years it has been updated a number of times to accommodate current knowledge [5]. The most recent version refers to “a substrate that is selectively utilized by host microorganisms conferring a health benefit” [6]. Previously, the “selective utilization” mostly referred to *Bifidobacterium* and *Lactobacillus*, whereas it is recognized today that prebiotic effects on the microbiota probably extend beyond these species. Fructans (fructo-oligosaccharides (FOS) and inulin) and galactans (galacto-oligosaccharides

(GOS)) have been considered to be typical prebiotics [6]. *In vitro* studies and randomized controlled trials have shown that they stimulate the growth of *Bifidobacterium* populations [7,8], as well as certain butyrate-producing species [9,10]. In addition, numerous randomized controlled trials have demonstrated direct health benefits from GOS, FOS, and inulin, including the inhibition of pathogens, protective effects against cardiovascular disease, and the improvement of mineral bioavailability [11–13]. The increased production of short-chain fatty acids (SCFAs), following fermentation of prebiotics, is proposed to play a key role in their action mechanisms [14]. However, variations in prebiotic chemical structure, such as linkage type and the degree of polymerization, are known to affect their utilization by the gut microbiota, and thus SCFA output [15–17]. For GOS, most studies have been performed with the beta-linked form, whereas only a few studies exist on the prebiotic potential of alpha-linked GOS, and include a study that reported that the modulation of the microbiota composition is associated with beneficial effects on appetite [18–20].

Xylo-oligosaccharides (XOS) and beta-glucans are considered to be novel prebiotics [21,22] because, in contrast to inulin, FOS, and GOS, fewer studies have been performed to measure the health benefits related to the selective fermentation of XOS or beta-glucan by the host microbiota. XOS are sugar oligomers made up of xylose units, which are linked through beta-(1–4) linkages (Vazquez, 2000). In human studies, XOS consumption has been found to result in increased fecal *Bifidobacterium* populations, increased fecal concentrations of SCFAs, and reduced constipation in pregnant women [23,24]. Moreover, XOS supplementation was found to have effects on markers of immune function in healthy adults [25]. Studies with XOS also indicate the potential to improve the management of blood sugars and cholesterol [26,27]. Beta-glucan is a long-chain, soluble, viscous fiber that has physiological health benefits for cholesterol and glycemic control [28]. The prebiotic activity of beta-glucan from oat was demonstrated in rats [29] and more recently in an *in vitro* study [18].


In the present study, we investigated the fermentation profiles, including the production of SCFAs, of different dietary fibers with a range of concentrations (inulin, alpha-GOS, beta-GOS, XOS from corn cobs and high-fiber sugar cane, and beta-glucan), in comparison with a positive control (FOS) and a negative control (no fiber addition), using the intestinal microbiota fermentation screening (i-screen) platform.

2. Results

2.1. Effect of Fibers on Microbiota Composition

2.1.1. Quantification of *Bifidobacterium* spp. and *Lactobacillus* Groups by Quantitative PCR (qPCR)

The effect of the different fibers on *Bifidobacterium* spp. and *Lactobacillus* populations was assessed after 24 h of fermentation using qPCR (Figure 1). For all tested fibers, except beta-glucan, an increase in *Bifidobacterium* spp. was observed after 24 h of fermentation (Figure 1A). Alpha-GOS appeared to increase *Bifidobacterium* spp. to a greater extent than FOS, at a concentration of 4 mg/mL. Moreover, the increase in *Bifidobacterium* spp. seemed to occur in a dose-dependent manner for all fibers, except beta-glucan. Alpha-GOS also resulted in an increase in *Bifidobacterium* spp. in the order of approximately 15-fold, compared to an eight-fold increase for beta-GOS, at concentrations of 2 and 4 mg/mL. Inulin and FOS had no effect on *Lactobacillus* groups 1 and 2, whereas there was an increase in these populations for all other fibers (Figure 1B,C). These population increases were moderate, with the exception of beta-glucan at a concentration of 12 mg/mL, which stood out despite a large standard deviation. The changes observed in *Lactobacillus* groups 1 and 2 for alpha-GOS versus beta-GOS, as well as for xylo-oligosaccharides from corn cobs (XOS-C) versus XOS from high-fiber sugar cane (XOS-S), were comparable.



2.1.2. Microbiota Profile Determined by 16S rRNA Gene Amplicon Sequencing

An overall representation of the results for the microbiota is given in Figure 2, which shows a clustering tree, based on a Bray–Curtis dissimilarity comparison, of all the data, except the 0.5 mg/mL fiber concentration that only had minor effects. The analysis illustrated that the effect of FOS on the microbiota was similar to inulin, as these samples clustered close to each other. Alpha-GOS-enriched samples showed changes similar to beta-GOS. For XOS-S, the duplicates appeared in two separate branches of the clustering tree, which indicated a large variance in the effects of this fiber on the microbiota. The beta-glucan samples clustered together and corresponded to an independent branch in the clustering tree, which indicated distinct changes in the composition of the microbiota compared to the other fibers.

The impact of the individual fiber substrates on the microbial taxa is displayed at the phylum and genus levels (Figures S1 and S2). With a relative abundance of 65%, Firmicutes was the dominant phylum in the untreated control, whereas Bacteroidetes and Actinobacteria accounted for 15% and 13%, respectively (Figure S1). The positive FOS control displayed a three-fold increase in Actinobacteria abundance at the expense of a 15% reduction in Firmicutes abundance, compared to the untreated control. This trend was observed across all fibers and appeared to be dose-dependent. Furthermore, there appeared to be a dose-dependent decrease in the relative abundance of Proteobacteria across all fibers. Genus-level profiles displayed a high and stable relative abundance of *Bacteroides* in the beta-glucan samples (Figure S2). This was also the case for XOS-C, whereas for all other fibers the abundance of *Bacteroides* decreased in a concentration-dependent manner.

Linear Discriminant Analysis (LDA), or LDA Effect Size (LEfSe) analysis, was applied to sequences at the genus level in order to identify changes in the microbial composition between untreated controls and the different fibers (Figure 3). Across all fibers, except beta-glucan, *Bifidobacterium* exhibited the largest LDA score, which indicated that it was the most enriched genus compared to the untreated control. For beta-glucan, *Prevotella* and *Roseburia* were the most enriched genera and displayed the largest LDA scores. *Clostridium* cluster XI was the most distinguishing genus in the untreated control sample compared to all the fiber-treated samples, except for XOS-S of which *Allisonella* was the largest distinguishing genus.

The Shannon index, which accounts for species abundance and evenness, was calculated to assess the alpha-diversity of the samples (Table S1). All individual fiber substrates showed a decrease in alpha-diversity with increasing fiber concentrations.

2.2. Impact of Fibers on Metabolites

The SCFAs acetate, propionate, butyrate, isovalerate, and isobutyrate could be detected in all fermentation samples (Figure 4). The individual SCFA production measurements can be seen in Table S2. Across all fibers, the total concentrations of SCFAs consistently increased with increasing fiber concentration. It is noteworthy that at 12 mg/mL of XOS-S, the total concentration of SCFAs surpassed that observed for all other fibers; a concentration of 180.3 mg/mL of SCFAs was observed with XOS-S compared to 127.4 mg/mL with XOS-C. The relative percentage patterns of the metabolites were comparable among the different fibers, except for beta-glucan which showed a distinct increase in the percentage of propionate at the expense of acetate.

There appeared to be a dose-response effect for butyrate with both inulin and beta-glucan fibers. The increase in butyrate formation, from the lowest to the highest fiber concentrations, was 7.9 to 25.5 mg/mL and 8.7 to 25.1 mg/mL for inulin and beta-glucan, respectively (Table S3).

The branched-chain fatty acid (BCFA) concentrations were low in all samples (0.91–5.77 mg/mL and 0.16–2.41 mg/mL for isovalerate and isobutyrate, respectively). The relative percentages of isobutyrate and isovalerate decreased in a concentration-dependent manner for all fibers, with the exception of beta-glucan for which the ratios remained essentially unchanged.




Figure 2. Clustering tree based on the Bray-Curtis dissimilarity of microbiota composition data, assessed by 16S rRNA gene amplicon sequencing. The number after the fiber indicates the concentration (in mg/mL) at which the fiber was added to the fermentation medium. The fiber concentration of 0.5 mg/mL is not depicted.




Figure 3. Identification of the most differentially abundant genera, between untreated controls and the fiber samples, using Linear Discriminant Analysis Effect Size (LEfSe) analysis. Genera enriched in the untreated samples are indicated with a positive Linear Discriminant Analysis (LDA) score (green), and genera enriched in the samples treated with different fibers are indicated with a negative LDA score (red). The threshold on the logarithmic LDA score for a discriminative genus was set to >2.0. (A) FOS, (B) Beta-GOS, (C) Inulin, (D) Beta-glucan, (E) XOS-S, (F) XOS-C, and (G) Alpha-GOS.




Figure 4. Total short-chain fatty acid (SCFA) concentrations and the relative percentages of SCFAs in the control and fiber-enriched samples. Acetate, propionate, butyrate, isovalerate, and isobutyrate were detected using gas chromatography (GC), and the total SCFA concentrations represent all metabolites measured.

2.3. Dependence between the Microbiota and Metabolite Production

We visualized the relationship between the composition of the microbiota and the levels of SCFAs using canonical correspondence analysis (CCA) (Figure 5). Previous observations of the distinct effect of beta-glucan on the microbial composition were hereby reaffirmed in the CCA, where the samples fermented with beta-glucan at concentrations of 4, 8 and 12 mg/mL were segregated from all other samples. This appeared to be explained by the differences observed in the propionate levels for beta-glucan compared to the other fibers.




Figure 5. Relationship between the composition of the microbiota and the levels of short-chain fatty acids (SCFAs), using correspondence analysis. The larger dots represent microbiome composition and show the centroid values for each of the sets of duplicate samples. Arrows represent the direction of the association of microbiome composition with specific SCFA levels.

3. Discussion

The aim of the present study was to compare the effects of various dietary fiber types and concentrations on the microbial ecology of the human gut, using the i-screen platform to represent the large intestine. Previously, the i-screen model was validated with a concentration of 4.2 mg/mL of prebiotic [30]. Here, we investigated fibers in a concentration range of 0.5 to 12 mg/mL to capture dosage-dependent effects.

We found that all of the investigated fibers showed prebiotic effects, in terms of selective utilization by the microbiota. A bifidogenic effect was measured, with qPCR and gene amplicon sequencing, for all fibers except beta-glucan. At the phylum level, this effect emerged as an increase in the abundance of Actinobacteria. This is in line with several *in vivo* and *in vitro* studies that demonstrated bifidogenic effects of fructans and galactans [8,10,31–33], including alpha-GOS [34]. In addition, similar effects were also shown for XOS [35,36]. An increase in bifidobacteria can be regarded as a marker of

intestinal health, with several studies demonstrating beneficial effects of this species on colorectal cancer, colon regularity, and acute diarrhea [37,38]. We observed no clear selective fermentation effect of *Bifidobacterium* in samples fermented with beta-glucan, which is consistent with other *in vitro* studies [39–41].

An enrichment of *Lactobacillus* spp. has been reported in some cases for GOS and FOS [42,43]. Our data showed an increase in lactobacilli mainly for beta-glucan, which has also been previously reported in the fecal microbiota of rats supplemented with beta-glucan [44], as well as in batch fermentation experiments [41]. However, there are also reports of beta-glucan having no effect on *Lactobacillus* spp. [39,40], suggesting that the effect might be dose-dependent because in our study a significant increase was observed only at the highest concentration.

The phylum Bacteroidetes and the genera *Prevotella* (members of Bacteroidetes) and *Roseburia* (members of Firmicutes) were most enhanced in response to beta-glucan. Both genera are abundant in the human gut [45,46]. *Prevotella* is associated with a high-fiber diet [47,48], and an increased abundance of *Roseburia* was observed in human volunteers on a diet high in resistant starch [49]. The increase in *Prevotella* in response to beta-glucan treatment is in agreement with a previous *in vitro* fermentation study [40], and may be partly explained by the presence of genes that are responsible for endo-beta-glucanase production, an enzyme essential for the digestion of beta-glucans [50,51]. A positive contribution of *Prevotella* to glucose tolerance was previously displayed in mice fed a high-fiber diet [48]. Notably, in our study, the increase in *Prevotella* with increasing concentrations of beta-glucan did not negatively affect the stable abundance of *Bacteroides*. This is in contrast to the often-observed inverse correlation of the two genera [52].

Microbial SCFAs have been shown to contribute significantly to host health within the gut and in the periphery [53]. Here, we found a dose-dependent increase in total SCFA concentrations for all fibers. Both forms of GOS and XOS induced an increased relative ratio of acetate. Acetate production pathways are widely distributed among bacterial groups in the gut [53]. It has been suggested that acetate has a direct role in central appetite regulation [54]. Additionally, acetate is known to undergo bacterial transformation into other metabolites, including butyrate, by so-called cross-feeding processes [55]. In the beta-glucan samples, we measured a higher propionate production compared to all other fibers, which may be explained by the promotion of *Prevotella*, a genus that contains important propionate-producing species, and *Roseburia*, which is one of the few genera that produces both butyrate and propionate [56]. Propionate has potential health-promoting effects due to its anti-lipogenic, cholesterol-lowering, anti-inflammatory, and anti-carcinogenic actions [57]. Furthermore, this SCFA may also play a role in appetite regulation [58].

Notably, the butyrate ratio increased with increasing concentrations of beta-glucan and inulin. Butyrate is an important energy source for intestinal epithelial cells and is believed to counteract colorectal cancer and inflammation [59]. This may be linked to the observed stimulation of the butyrate-producing species *Ruminococcus* and *Roseburia* by inulin and beta-glucan, respectively.

It was previously shown that variations in the chemical structure of a prebiotic can impact its selective fermentation by bacteria [60–62]. Here, we compared both GOS and XOS from different sources. The fermentation of beta-GOS and alpha-GOS resulted in comparable microbial and metabolic profiles. XOS of different origins (high-fiber sugar cane or corn cobs) also displayed similar effects on the composition of the microbiota and SCFA production, but some differences were observed at high concentrations, potentially due to the variations in purity as has been previously pointed out [62].

Clinical studies investigating prebiotic effects have some disadvantages with respect to ethical constraints, as well as limited sampling possibilities from the colon and limited measurements of *in situ* SCFA production, but these constraints are eliminated by applying an *in vitro* approach. However, the batch fermentation used in this study also has some limitations. The standardized fecal inoculum was pre-cultured at a pH of 5.8, which may have impacted the initial microbial composition of the fecal sample. However, it was previously reported that the compositional and metabolic changes in response to pre-culturing are insignificant [63]. Moreover, the stimulation of selected bacterial species,

and the subsequent increase in metabolite production, led to a reduction in pH and thus a growth inhibition of some species. It is likely that the lack of pH control was the reason for the dose-dependent decrease in alpha-diversity that we observed for all tested fibers, which is a general phenomenon for batch fermentation experiments. An additional limitation was the short fermentation time of 24 h that failed to capture the complete picture of cross-feeding interactions between gut microbes, and which may not fully correlate with the long-term effects of fibers on the microbiota.

In conclusion, this study revealed changes in the adult fecal microbial ecology upon fermentation with different fibers. Many of the observed compositional and metabolic changes for typical prebiotics were in accordance with previous *in vitro* and *in vivo* data, thus confirming the suitability of the i-screen fermentation platform for the screening of novel prebiotic compounds. Our fermentation results support the prebiotic activity of alpha-GOS, XOS, and beta-glucan. The effects of XOS and alpha-GOS on the microbiota and metabolite production can be considered “prebiotic” in the classical sense of their ability to increase bifidobacterial populations. Beta-glucan, on the other hand, induced distinct changes compared to well-established prebiotics. The observed increases in butyrate and propionate may be linked to the health benefits of beta-glucan. Further *in vivo* human studies may help to strengthen the link between the beneficial health effects of beta-glucan, notably on glucose metabolism, and the changes induced in the gut microbiota.

4. Materials and Methods

4.1. Fibers

The characteristics of the fibers (FOS, inulin, alpha-GOS, beta-GOS, XOS-C, XOS-S and beta-glucan) investigated in the i-screen fermentation platform are described in Table 1.

Table 1. Characteristics of fibers used in the *in vitro* fermentation.

Fiber	Source	Purity	Supplier
FOS	Chicory root	≥90%	Sigma-Aldrich, Zwijndrecht, The Netherlands
Inulin	Chicory root	≥99.5%	SENSUS, Roosendaal, The Netherlands
Alpha-GOS	Peas	≥95%	SAS Olygose, Venette, France
Beta-GOS	Lactose	90%	Hylan Co., Qingdao, China
XOS-C	Corn cobs	≥95%	Longlive Biotechnology Co., Shandong, China
XOS-S	Sugar cane fiber	≥75%	Prenexus Health Inc., Gilbert, AZ, USA
Beta-glucan	Oat flour	>94%	Megazyme, Wicklow, Ireland

4.2. Fecal Inoculum

As an inoculum for the i-screen platform, a standardized human adult intestinal microbiota sample was used. Fecal samples were collected from six healthy adult volunteers (Caucasian individuals, subject to a European lifestyle and nutrition, and no antibiotic usage in the last three months) in a closed box with an anaerobic strip (AnaeroGen, Oxoid, Cambridge, UK) inside, as described previously [63]. To create the standardized microbiota, pooled stools were grown in a fed-batch fermenter for 40 h. The fermentation medium was based on the standard ileal efflux medium (SIEM) composition [64] that was modified as described previously [63] and adjusted to a pH of 5.8. This standard adult gut microbiota was stored at −80 °C in 12% glycerol. Collection of fecal samples was performed anonymously following TNO standard operational procedures, which was approved by an internal ethical evaluation board and is in compliance with the Dutch laws on medical/scientific research. Participants gave written informed consent.

4.3. Experimental Set-Up

Before starting the i-screen incubations with the test materials, the standardized fecal inoculum was incubated in the modified SIEM overnight (37 °C; 300 rpm) using a Whitley A45 anaerobic cabinet

(Kentron Microbiology BV, Doetinchem, the Netherlands) and an 80% N₂/10% CO₂/10% H₂ gas mixture to activate the fecal bacteria. Then, the fibers were mixed with SIEM and the 1% (*v/v*) fecal inoculum in each well of a deep-well plate. Five concentrations (0.5, 2, 4, 8, and 12 mg/mL) of inulin, alpha-GOS, beta-GOS, XOS-C, XOS-S, and beta-glucan fibers were tested in duplicate. Due to viscosity issues, the two highest concentrations of beta-glucan (8 and 12 mg/mL) had to be weighed into the test wells directly and were not dissolved beforehand. Inoculated SIEM without fiber was used as a negative control, and supplementation with FOS at 4 mg/mL was used as a positive prebiotic control. Both controls were included in triplicate. After 24 h of fermentation, collected samples were directly stored at −20 °C for subsequent DNA isolation and SCFA analysis.

4.4. DNA Isolation

Total DNA from collected samples was isolated as described by Ladirat et al. [63] with some minor adjustments: The samples were initially mixed with 300 µL of lysis buffer (Agowa, Berlin, Germany), 500 µL of zirconium beads (0.1 mm), and 500 µL of phenol, before being placed in a BeadBeater (BioSpec Products, Bartlesville, OK, USA) for 3 min.

4.5. Quantitative PCR (qPCR)

Total DNA was used for qPCR analyses using TaqMan chemistry. The primers and probes used to quantify the total number of bacteria in *Lactobacillus* group 1 (which includes *L. gasseri*, *L. helveticus*, *L. johnsonii*, *L. amylovorus*, *L. acidophilus*, *L. delbrueckii*, *L. crispatus*, *L. jensenii*, *L. amylolyticus*, and *L. kefirifaciens*), *Lactobacillus* group 2 (which includes *L. casei*, *L. plantarum*, *L. brevis*, *L. salivarius*, *L. paracasei*, *L. reuteri*, *L. rhamnosus*, *L. buchneri*, *L. fermentum*, *L. pentosus*, *L. animalis*, *L. sakei*, and *L. murinus*), and *Bifidobacterium* spp. are described in Table S3.

qPCR was performed on an Applied Biosystems 7500 thermal cycler, using the TaqMan[®] Fast Universal PCR Master Mix. For the real-time PCR, 5 µL of DNA, 12.5 µL of TaqMan[®] Fast Universal PCR Master Mix, 1 µL (10 pmol) of forward and reverse primers, and 1 µL (5 pmol) of TaqMan probe were mixed, and 4.5 µL of DNase-free water was added, to make a final volume of 25 µL. The cycling conditions consisted of 3 min at 95 °C, followed by 45 cycles of 3 s at 95 °C, and then 30 s at 60 °C. Real-time data were analyzed with Applied Biosystems 7500 software (Version 1.4). Upon completion of the run, a cycle threshold (Ct) was calculated. Relative fold change values were obtained by the $\Delta\Delta C_t$ method, where all results are normalized to the 16S data (ΔC_t) and the untreated control samples are utilized as the control ($\Delta\Delta C_t$).

4.6. 16S rRNA Gene Amplicon Sequencing and Analysis

To determine changes in the composition of the microbiota of fermentation samples with individual fiber substrates, 16S rRNA gene amplicon sequencing was performed. A total of 100 pg of DNA was amplified, targeting the V4 hypervariable region, using the F515/R806 primers as described previously [65], with the exception that 30 cycles were used instead of 35 [66]. Primers included Illumina adapter sequences and a unique 8-nt sample index sequence key [65]. To determine the amount of bacterial DNA, qPCR, using primers specific for the bacterial 16S rRNA gene, was carried out. The amplicon libraries were pooled in equimolar amounts and purified using the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany). Amplicon quality and size were analyzed on a Fragment Analyzer (Advanced Analytical Technologies, Inc., Heidelberg, Germany). Paired-end sequencing of amplicons were conducted on the Illumina MiSeq platform (Illumina, Eindhoven, The Netherlands).

Pre-processing, analysis, and classifications of sequencing data were performed using modules implemented in the Mothur software platform [67]. Chimeric sequences were identified and removed using the chimera.uchime command. Unique 16S rRNA sequences were aligned using the align.seqs command and the Mothur-compatible Bacterial SILVA SEED database (Release 119; available online: https://mothur.org/wiki/Silva_reference_files). Bacterial sequences were taxonomically classified by the RDP-II Naïve Bayesian Classifier using a 60% confidence threshold against the RDP Database

(Release 11.1; available online: https://www.mothur.org/wiki/RDP_reference_files) for 16S rRNA. Richness and diversity including the Shannon diversity index were calculated.

4.7. Gas Chromatography Analysis

SCFAs (acetate, propionate, and n-butyrate) and BCFAs (isobutyrate and isovalerate) were analyzed as described by Jouany [68], and modified slightly as described by Van Nuenen [69]. In brief, exposed material from the i-screen samples was centrifuged ($\sim 12,000\times g$, 5 min) and the cleared supernatant was filter sterilized (0.45 μm). A mixture of formic acid (20%), methanol, and 2-ethyl butyric acid (internal standard, 2 mg/mL in methanol) was added. A 3 μL sample, with a split ratio of 75.0, was injected on a GC-column (ZB-5HT inferno, ID 0.52 mm, film thickness 0.10 μm ; Zebron, Phenomenex, Torrance, CA, USA) in a Shimadzu GC-2014 gas chromatograph (Shimadzu Europa GmbH, Duisburg, Germany).

4.8. Statistical Analysis

All qPCR data are reported as the mean \pm SD of duplicates which does not allow for statistical inference and hypothesis testing.

Statistical analysis of the 16S rRNA amplicon sequencing data was performed using LEfSe [70]. For the LEfSe analysis, the non-parametric factorial Kruskal-Wallis (KW) sum-rank test, with an alpha of 0.05, was used to detect genera with significant differential abundance of each fiber with respect to the control. The biological significance was subsequently investigated using a set of pairwise tests among the different fiber concentrations and the control, using the (unpaired) Wilcoxon rank-sum test with an alpha of 0.05. As a last step, LEfSe uses Linear Discriminant Analysis to estimate the effect size of each differentially abundant genus. The threshold on the logarithmic LDA score for a differentially abundant genus was set to >2.0 .

16S rRNA gene amplicon sequencing data and environmental variables (SCFA levels) were ordinated using CCA as implemented in the R package “vegan” [71], in R version 3.4.4 [72]. Canonical correspondence analysis is a multivariate constrained ordination technique that extracts major gradients among combinations of explanatory variables. The same package was used to calculate the Shannon index of alpha-diversity. Distance based analyses (CCA and clustering) were performed using the Bray-Curtis dissimilarity measure.

4.9. Data Availability

All DNA sequences presented in this study will be deposited in the sequence read archive (SRA) of the NCBI database.

Supplementary Materials: Supplementary materials can be found at <http://www.mdpi.com/1422-0067/19/10/3097/s1>.

Author Contributions: K.P., J.K., F.H.J.S., R.E.S., and D.R. conceived and designed the experiments; F.H.J.S. and J.K. supervised the completion of the experiments; M.H. and T.v.d.B. conducted the bioinformatics analysis; S.F., J.K., M.H., T.v.d.B., F.H.J.S., R.E.S., and D.R. interpreted the results; S.F. wrote the paper. All authors read and approved the final version of the manuscript.

Acknowledgments: SAS Olygose, Longlive Biotechnology, and Prenexus Health are gratefully acknowledged for providing alpha-GOS, XOS-C, and XOS-S products for the experiment.

Conflicts of Interest: S.F., K.P., R.E.S., and D.R. are employees of DSM Nutritional Products, which is involved in the commercialization of dietary fibers.

References

1. Guarner, F.; Malagelada, J.R. Gut flora in health and disease. *Lancet* **2003**, *361*, 512–519. [[CrossRef](#)]
2. Carding, S.; Verbeke, K.; Vipond, D.T.; Corfe, B.M.; Owen, L.J. Dysbiosis of the gut microbiota in disease. *Microb. Ecol. Health Dis.* **2015**, *26*, 26191. [[CrossRef](#)] [[PubMed](#)]

3. Marchesi, J.R.; Adams, D.H.; Fava, F.; Hermes, G.D.; Hirschfield, G.M.; Hold, G.; Quraishi, M.N.; Kinross, J.; Smidt, H.; Tuohy, K.M.; et al. The gut microbiota and host health: A new clinical frontier. *Gut* **2016**, *65*, 330–339. [[CrossRef](#)] [[PubMed](#)]
4. Gibson, G.R.; Roberfroid, M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. *J. Nutr.* **1995**, *125*, 1401–1412. [[PubMed](#)]
5. Hutkins, R.W.; Krumbeck, J.A.; Bindels, L.B.; Cani, P.D.; Fahey, G., Jr.; Goh, Y.J.; Hamaker, B.; Martens, E.C.; Mills, D.A.; Rastal, R.A.; et al. Prebiotics: Why definitions matter. *Curr. Opin. Biotechnol.* **2016**, *37*, 1–7. [[CrossRef](#)] [[PubMed](#)]
6. Gibson, G.R.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; Scott, K.; Stanton, C.; Swanson, K.S.; Cani, P.D.; et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat. Rev. Gastroenterol. Hepatol.* **2017**, *14*, 491–502. [[CrossRef](#)] [[PubMed](#)]
7. Sawicki, C.M.; Livingston, K.A.; Obin, M.; Roberts, S.B.; Chung, M.; McKeown, N.M. Dietary fiber and the human gut microbiota: Application of evidence mapping methodology. *Nutrients* **2017**, *9*, 125. [[CrossRef](#)] [[PubMed](#)]
8. Roberfroid, M.B.; Van Loo, J.A.; Gibson, G.R. The bifidogenic nature of chicory inulin and its hydrolysis products. *J. Nutr.* **1998**, *128*, 11–19. [[CrossRef](#)] [[PubMed](#)]
9. Scott, K.P.; Martin, J.C.; Duncan, S.H.; Flint, H.J. Prebiotic stimulation of human colonic butyrate-producing bacteria and bifidobacteria, *in vitro*. *FEMS Microbiol. Ecol.* **2014**, *87*, 30–40. [[CrossRef](#)] [[PubMed](#)]
10. Ramirez-Farias, C.; Slezak, K.; Fuller, Z.; Duncan, A.; Holtrop, G.; Louis, P. Effect of inulin on the human gut microbiota: Stimulation of *Bifidobacterium adolescentis* and *Faecalibacterium prausnitzii*. *Br. J. Nutr.* **2009**, *101*, 541–550. [[CrossRef](#)] [[PubMed](#)]
11. Kellow, N.J.; Coughlan, M.T.; Reid, C.M. Metabolic benefits of dietary prebiotics in human subjects: A systematic review of randomised controlled trials. *Br. J. Nutr.* **2014**, *111*, 1147–1161. [[CrossRef](#)] [[PubMed](#)]
12. Lohner, S.; Kullenberg, D.; Antes, G.; Decsi, T.; Meerpohl, J.J. Prebiotics in healthy infants and children for prevention of acute infectious diseases: A systematic review and meta-analysis. *Nutr. Rev.* **2014**, *72*, 523–531. [[CrossRef](#)] [[PubMed](#)]
13. Abrams, S.A.; Griffin, I.J.; Hawthorne, K.M.; Liang, L.; Gunn, S.K.; Darlington, G.; Ellis, K.J. A combination of prebiotic short- and long-chain inulin-type fructans enhances calcium absorption and bone mineralization in young adolescents. *Am. J. Clin. Nutr.* **2005**, *82*, 471–476. [[CrossRef](#)] [[PubMed](#)]
14. den Besten, G.; van Eunen, K.; Groen, A.K.; Venema, K.; Reijngoud, D.J.; Bakker, B.M. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J. Lipid Res.* **2013**, *54*, 2325–2340. [[CrossRef](#)] [[PubMed](#)]
15. Hamaker, B.R.; Tuncil, Y.E. A perspective on the complexity of dietary fiber structures and their potential effect on the gut microbiota. *J. Mol. Biol.* **2014**, *426*, 3838–3850. [[CrossRef](#)] [[PubMed](#)]
16. van de Wiele, T.; Boon, N.; Possemiers, S.; Jacobs, H.; Verstraete, W. Inulin-type fructans of longer degree of polymerization exert more pronounced *in vitro* prebiotic effects. *J. Appl. Microbiol.* **2007**, *102*, 452–460. [[CrossRef](#)] [[PubMed](#)]
17. Mendis, M.; Martens, E.C.; Simsek, S. How fine structural differences of xylooligosaccharides and arabinoxylooligosaccharides regulate differential growth of *Bacteroides* species. *J. Agric. Food Chem.* **2018**, *66*, 8398–8405. [[CrossRef](#)] [[PubMed](#)]
18. Poeker, S.A.; Geirnaert, A.; Berchtold, L.; Greppi, A.; Krych, L.; Steinert, R.E.; de Wouters, T.; Lacroix, C. Understanding the prebiotic potential of different dietary fibers using an *in vitro* continuous adult fermentation model (PolyFermS). *Sci. Rep.* **2018**, *8*, 4318. [[CrossRef](#)] [[PubMed](#)]
19. Hernandez-Hernandez, O.; Cote, G.L.; Kolida, S.; Rastall, R.A.; Sanz, M.L. *In vitro* fermentation of alternansucrase raffinose-derived oligosaccharides by human gut bacteria. *J. Agric. Food Chem.* **2011**, *59*, 10901–10906. [[CrossRef](#)] [[PubMed](#)]
20. Morel, F.B.; Dai, Q.; Ni, J.; Thomas, D.; Parnet, P.; Fanca-Berthon, P. Alpha-galacto-oligosaccharides dose-dependently reduce appetite and decrease inflammation in overweight adults. *J. Nutr.* **2015**, *145*, 2052–2059. [[CrossRef](#)] [[PubMed](#)]
21. Lomax, A.R.; Calder, P.C. Prebiotics, immune function, infection and inflammation: A review of the evidence. *Br. J. Nutr.* **2009**, *101*, 633–658. [[CrossRef](#)] [[PubMed](#)]

22. Lam, K.L.; Cheung, C.K. Non-digestible long chain beta-glucans as novel prebiotics. *Bioact. Carbohydr. Dietary Fibre* **2013**, *2*, 45–64. [[CrossRef](#)]
23. Tateyama, I.; Hashii, K.; Johno, I.; Iino, T.; Hirai, K.; Suwa, Y.; Kiso, Y. Effect of xylooligosaccharides intake on severe constipation in pregnant woman. *Nutr. Sci. Vitaminol.* **2005**, *51*, 445–448. [[CrossRef](#)]
24. Chung, Y.-C.; Hsu, C.-K.; Ko, C.-Y.; Chan, Y.-C. Dietary intake of xylooligosaccharides improves the intestinal microbiota, fecal moisture, and pH value in the elderly. *Nutr. Res.* **2007**, *27*, 756–761. [[CrossRef](#)]
25. Childs, C.E.; Roytio, H.; Alhoniemi, E.; Fekete, A.A.; Forssten, S.D.; Hudjec, N.; Lim, Y.N.; Steger, C.J.; Yaqoob, P.; Tuohy, K.M.; et al. Xylo-oligosaccharides alone or in synbiotic combination with *Bifidobacterium animalis* subsp. *lactis* induce bifidogenesis and modulate markers of immune function in healthy adults: A double-blind, placebo-controlled, randomised, factorial cross-over study. *Br. J. Nutr.* **2014**, *111*, 1945–1956. [[PubMed](#)]
26. Yang, J.; Summanen, P.H.; Henning, S.M.; Hsu, M.; Lam, H.; Huang, J.; Tseng, C.H.; Dowd, S.E.; Finegold, S.M.; Heber, D.; et al. Xylooligosaccharide supplementation alters gut bacteria in both healthy and prediabetic adults: A pilot study. *Front. Physiol.* **2015**, *6*, 216. [[CrossRef](#)] [[PubMed](#)]
27. Sheu, W.H.; Lee, I.T.; Chen, W.; Chan, Y.C. Effects of xylooligosaccharides in type 2 diabetes mellitus. *J. Nutr. Sci. Vitaminol.* **2008**, *54*, 396–401. [[CrossRef](#)] [[PubMed](#)]
28. El Khoury, D.; Cuda, C.; Luhovyy, B.L.; Anderson, G.H. Beta glucan: Health benefits in obesity and metabolic syndrome. *J. Nutr. Metab.* **2012**, *2012*, 851362. [[CrossRef](#)] [[PubMed](#)]
29. Shen, R.L.; Dang, X.Y.; Dong, J.L.; Hu, X.Z. Effects of oat beta-glucan and barley beta-glucan on fecal characteristics, intestinal microflora, and intestinal bacterial metabolites in rats. *J. Agric. Food Chem.* **2012**, *60*, 11301–11308. [[CrossRef](#)] [[PubMed](#)]
30. Ladirat, S.E.; Schuren, F.H.; Schoterman, M.H.; Nauta, A.; Gruppen, H.; Schols, H.A. Impact of galacto-oligosaccharides on the gut microbiota composition and metabolic activity upon antibiotic treatment during *in vitro* fermentation. *FEMS Microbiol. Ecol.* **2014**, *87*, 41–51. [[CrossRef](#)] [[PubMed](#)]
31. Davis, L.M.; Martinez, I.; Walter, J.; Goin, C.; Hutkins, R.W. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. *PLoS ONE* **2011**, *6*, e25200. [[CrossRef](#)] [[PubMed](#)]
32. Vulevic, J.; Juric, A.; Walton, G.E.; Claus, S.P.; Tzortzis, G.; Toward, R.E.; Gibson, G.R. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabolomics in elderly persons. *Br. J. Nutr.* **2015**, *114*, 586–595. [[CrossRef](#)] [[PubMed](#)]
33. Liu, F.; Li, P.; Chen, M.; Luo, Y.; Prabhakar, M.; Zheng, H.; He, Y.; Qi, Q.; Long, H.; Zhang, Y.; et al. Fructooligosaccharide (FOS) and galactooligosaccharide (GOS) increase *Bifidobacterium* but reduce butyrate producing bacteria with adverse glycemic metabolism in healthy young population. *Sci. Rep.* **2017**, *7*, 11789. [[CrossRef](#)] [[PubMed](#)]
34. Dai, Z.; Lyu, W.; Xie, M.; Yuan, Q.; Ye, H.; Hu, B.; Zhou, L.; Zeng, X. Effects of alpha-galactooligosaccharides from chickpeas on high-fat-diet-induced metabolic syndrome in mice. *J. Agric. Food Chem.* **2017**, *65*, 3160–3166. [[CrossRef](#)] [[PubMed](#)]
35. Moniz, P.; Ho, A.L.; Duarte, L.C.; Kolida, S.; Rastall, R.A.; Pereira, H.; Carvalheiro, F. Assessment of the bifidogenic effect of substituted xylo-oligosaccharides obtained from corn straw. *Carbohydr. Polym.* **2016**, *136*, 466–473. [[CrossRef](#)] [[PubMed](#)]
36. Lecerf, J.M.; Depeint, F.; Clerc, E.; Dugenet, Y.; Niamba, C.N.; Rhazi, L.; Cayzeele, A.; Abdelnour, G.; Jaruga, A.; Younes, H.; et al. Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. *Br. J. Nutr.* **2012**, *108*, 1847–1858. [[CrossRef](#)] [[PubMed](#)]
37. Roberfroid, M.; Gibson, G.R.; Hoyle, L.; McCartney, A.L.; Rastall, R.; Rowland, I.; Wolvers, D.; Watzl, B.; Szajewska, H.; Stahl, B.; et al. Prebiotic effects: Metabolic and health benefits. *Br. J. Nutr.* **2010**, *104* (Suppl. 2), S1–S63. [[CrossRef](#)] [[PubMed](#)]
38. O’Callaghan, A.; van Sinderen, D. Bifidobacteria and their role as members of the human gut microbiota. *Front. Microbiol.* **2016**, *7*, 925. [[CrossRef](#)] [[PubMed](#)]
39. Yang, J.; Martinez, I.; Walter, J.; Keshavarzian, A.; Rose, D.J. *In vitro* characterization of the impact of selected dietary fibers on fecal microbiota composition and short chain fatty acid production. *Anaerobe* **2013**, *23*, 74–81. [[CrossRef](#)] [[PubMed](#)]

40. Hughes, S.A.; Shewry, P.R.; Gibson, G.R.; McCleary, B.V.; Rastall, R.A. *In vitro* fermentation of oat and barley derived beta-glucans by human faecal microbiota. *FEMS Microbiol. Ecol.* **2008**, *64*, 482–493. [[CrossRef](#)] [[PubMed](#)]
41. Lam, K.L.; Keung, H.Y.; Ko, K.C.; Kwan, H.S.; Cheung, P.C.K. *In vitro* fermentation of beta-glucans and other selected carbohydrates by infant fecal inoculum: An evaluation of their potential as prebiotics in infant formula. *Bioact. Carbohydr. Dietary Fibre* **2017**, *14*, 20–24. [[CrossRef](#)]
42. Ten Bruggencate, S.J.; Bovee-Oudenhoven, I.M.; Lettink-Wissink, M.L.; Katan, M.B.; van der Meer, R. Dietary fructooligosaccharides affect intestinal barrier function in healthy men. *J. Nutr.* **2006**, *136*, 70–74. [[CrossRef](#)] [[PubMed](#)]
43. Vulevic, J.; Drakoularakou, A.; Yaqoob, P.; Tzortzis, G.; Gibson, G.R. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. *Am. J. Clin. Nutr.* **2008**, *88*, 1438–1446. [[PubMed](#)]
44. Snart, J.; Bibiloni, R.; Grayson, T.; Lay, C.; Zhang, H.; Allison, G.E.; Laverdiere, J.K.; Temelli, F.; Vasanthan, T.; Bell, R.; et al. Supplementation of the diet with high-viscosity beta-glucan results in enrichment for lactobacilli in the rat cecum. *Appl Environ. Microbiol.* **2006**, *72*, 1925–1931. [[CrossRef](#)] [[PubMed](#)]
45. Arumugam, M.; Raes, J.; Pelletier, E.; Le Paslier, D.; Yamada, T.; Mende, D.R.; Fernandes, G.R.; Tap, J.; Bruls, T.; Batto, J.M.; et al. Enterotypes of the human gut microbiome. *Nature* **2011**, *473*, 174–180. [[CrossRef](#)] [[PubMed](#)]
46. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T.; et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* **2010**, *464*, 59–65. [[CrossRef](#)] [[PubMed](#)]
47. De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poulet, J.B.; Massart, S.; Collini, S.; Pieraccini, G.; Lionetti, P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 14691–14696. [[CrossRef](#)] [[PubMed](#)]
48. Kovatcheva-Datchary, P.; Nilsson, A.; Akrami, R.; Lee, Y.S.; De Vadder, F.; Arora, T.; Hallen, A.; Martens, E.; Bjorck, I.; Backhed, F. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of *Prevotella*. *Cell Metab.* **2015**, *22*, 971–982. [[CrossRef](#)] [[PubMed](#)]
49. Walker, A.W.; Ince, J.; Duncan, S.H.; Webster, L.M.; Holtrop, G.; Ze, X.; Brown, D.; Stares, M.D.; Scott, P.; Bergerat, A.; et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. *ISME J.* **2011**, *5*, 220–230. [[CrossRef](#)] [[PubMed](#)]
50. McGregor, N.; Morar, M.; Fenger, T.H.; Stogios, P.; Lenfant, N.; Yin, V.; Xu, X.; Evdokimova, E.; Cui, H.; Henrissat, B.; et al. Structure-function analysis of a mixed-linkage beta-glucanase/xyloglucanase from the key ruminal Bacteroidetes *Prevotella bryantii* B(1)4. *J. Biol. Chem.* **2016**, *291*, 1175–1197. [[CrossRef](#)] [[PubMed](#)]
51. Tamura, K.; Hemsworth, G.R.; Dejean, G.; Rogers, T.E.; Pudlo, N.A.; Urs, K.; Jain, N.; Davies, G.J.; Martens, E.C.; Brumer, H. Molecular mechanism by which prominent human gut Bacteroidetes utilize mixed-linkage beta-glucans, major health-promoting cereal polysaccharides. *Cell. Rep.* **2017**, *21*, 417–430. [[CrossRef](#)] [[PubMed](#)]
52. Gorvitovskaia, A.; Holmes, S.P.; Huse, S.M. Interpreting *Prevotella* and *Bacteroides* as biomarkers of diet and lifestyle. *Microbiome* **2016**, *4*, 15. [[CrossRef](#)] [[PubMed](#)]
53. Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes* **2016**, *7*, 189–200. [[CrossRef](#)] [[PubMed](#)]
54. Frost, G.; Sleeth, M.L.; Sahuri-Arisoylu, M.; Lizarbe, B.; Cerdan, S.; Brody, L.; Anastasovska, J.; Ghourab, S.; Hankir, M.; Zhang, S.; et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. *Nat. Commun.* **2014**, *5*, 3611. [[CrossRef](#)] [[PubMed](#)]
55. Duncan, S.H.; Holtrop, G.; Lobley, G.E.; Calder, A.G.; Stewart, C.S.; Flint, H.J. Contribution of acetate to butyrate formation by human faecal bacteria. *Br. J. Nutr.* **2004**, *91*, 915–923. [[CrossRef](#)] [[PubMed](#)]
56. Louis, P.; Flint, H.J. Formation of propionate and butyrate by the human colonic microbiota. *Environ. Microbiol.* **2017**, *19*, 29–41. [[CrossRef](#)] [[PubMed](#)]
57. Hosseini, E.; Grootaert, C.; Verstraete, W.; Van de Wiele, T. Propionate as a health-promoting microbial metabolite in the human gut. *Nutr. Rev.* **2011**, *69*, 245–258. [[CrossRef](#)] [[PubMed](#)]

58. Chambers, E.S.; Viardot, A.; Psichas, A.; Morrison, D.J.; Murphy, K.G.; Zac-Varghese, S.E.; MacDougall, K.; Preston, T.; Tedford, C.; Finlayson, G.S.; et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. *Gut* **2015**, *64*, 1744–1754. [[CrossRef](#)] [[PubMed](#)]
59. Hamer, H.M.; Jonkers, D.; Venema, K.; Vanhoutvin, S.; Troost, F.J.; Brummer, R.J. Review article: The role of butyrate on colonic function. *Aliment. Pharmacol. Ther.* **2008**, *27*, 104–119. [[CrossRef](#)] [[PubMed](#)]
60. Li, W.; Wang, K.; Sun, Y.; Ye, H.; Hu, B.; Zeng, X. Influences of structures of galactooligosaccharides and fructooligosaccharides on the fermentation *in vitro* by human intestinal microbiota. *J. Funct. Foods* **2015**, *13*, 10. [[CrossRef](#)]
61. Cardelle-Cobas, A.; Corzo, N.; Olano, A.; Pelaez, C.; Requena, T.; Avila, M. Galactooligosaccharides derived from lactose and lactulose: Influence of structure on *Lactobacillus*, *Streptococcus* and *Bifidobacterium* growth. *Int. J. Food Microbiol.* **2011**, *149*, 81–87. [[CrossRef](#)] [[PubMed](#)]
62. Makelainen, H.; Saarinen, M.; Stowell, J.; Rautonen, N.; Ouwehand, A.C. Xylo-oligosaccharides and lactitol promote the growth of *Bifidobacterium lactis* and *Lactobacillus* species in pure cultures. *Benef. Microbes* **2010**, *1*, 139–148. [[CrossRef](#)] [[PubMed](#)]
63. Ladirat, S.E.; Schols, H.A.; Nauta, A.; Schoterman, M.H.; Keijser, B.J.; Montijn, R.C.; Gruppen, H.; Schuren, F.H. High-throughput analysis of the impact of antibiotics on the human intestinal microbiota composition. *J. Microbiol. Methods* **2013**, *92*, 387–397. [[CrossRef](#)] [[PubMed](#)]
64. Minekus, M.; Smeets-Peeters, M.; Bernalier, A.; Marol-Bonin, S.; Havenaar, R.; Marteau, P.; Alric, M.; Fonty, G.; Veld, J.H.J.H.I. A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products. *Appl. Microbiol. Biotechnol.* **1999**, *53*, 108–114. [[CrossRef](#)] [[PubMed](#)]
65. Kozich, J.J.; Westcott, S.L.; Baxter, N.T.; Highlander, S.K.; Schloss, P.D. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. *Appl. Environ. Microbiol.* **2013**, *79*, 5112–5120. [[CrossRef](#)] [[PubMed](#)]
66. Caporaso, J.G.; Lauber, C.L.; Walters, W.A.; Berg-Lyons, D.; Lozupone, C.A.; Turnbaugh, P.J.; Fierer, N.; Knight, R. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proc. Natl. Acad. Sci. USA* **2011**, *108* (Suppl. 1), 4516–4522. [[CrossRef](#)]
67. Schloss, P.D.; Westcott, S.L.; Ryabin, T.; Hall, J.R.; Hartmann, M.; Hollister, E.B.; Lesniewski, R.A.; Oakley, B.B.; Parks, D.H.; Robinson, C.J.; et al. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl. Environ. Microbiol.* **2009**, *75*, 7537–7541. [[CrossRef](#)] [[PubMed](#)]
68. Jouany, J. Volatile fatty acid (VFA) and alcohol determination in digestive contents, silage juices, bacterial cultures and anaerobic fermentor contents. *Sci. Aliments* **1982**, *2*, 131–144.
69. Van Nuenen, M.H.M.C.; Meyer, P.D.; Venema, K. The effect of various inulins and *Clostridium difficile* on the metabolic activity of the human colonic microbiota *in vitro*. *Micriob. Ecol. Health Dis.* **2003**, *15*, 137–144.
70. Segata, N.; Izard, J.; Waldron, L.; Gevers, D.; Miropolsky, L.; Garrett, W.S.; Huttenhower, C. Metagenomic biomarker discovery and explanation. *Genome Biol.* **2011**, *12*, R60. [[CrossRef](#)] [[PubMed](#)]
71. Oksanen, J.; Blanchet, F.G.; Friendly, M.; Kindt, R.; Legendre, P.; McGlenn, D.; Minchin, P.R.; O'Hara, R.B.; Simpson, G.L.; Solymos, P.; et al. Vegan: Community Ecology Package. 2017. Available online: <https://CRAN.R-project.org/package=vegan> (accessed on 10 October 2018).
72. R Core Team. *R: A Language and Environment for Statistical Computing*; R Core Team: Vienna, Austria, 2016.

